Health  Vol.6 No.19 , November 2014
Progression of Cognitive Deficit in Older People with Mild Cognitive Impairment Treated with Cerebrolysin
Abstract: Objectives: Although people with amnestic mild cognitive impairment (aMCI) benefit from cerebrolysin treatment, some still develop dementia. The aim of the current study was to identify most informative clinical assessment tests to predict the therapy efficacy in aMCI subjects treated with cerebrolysin. Methods: We studied patients with amnestic mild cognitive impairment (aMCI; n = 53) who had regular neurocognitive and clinical psychiatric assessments and were treated with cerebrolysin i.v. infusions 20 × 30 ml twice a year over three years period. Data were analyzed using non-parametric statistics, cluster and linear discriminant analyses. Results: Combined mathematical modeling enabled to predict cognitive decline from aMCI to dementia in the cerebrolysin-treated patients based on their initial neurocognitive assessment scores. We identified a “dementia risk group” with fast cognitive decline (i.e. low efficacy of the treatment). Lower baseline scores in the Mattis Dementia Rating Scale Memory subtest, Mini-Mental State Examination (MMSE), 10 word list immediate recall, and Frontal Assessment Battery tests when accompanied by higher depression score (Hamilton Depression Rating Scale) suggest poor prognosis for aMCI patients treated with cerebrolysin. Changes in scores on the MMSE, Boston naming test, Digit span forward, and Wechsler scale subtest “Categorical associations” during the treatment course are more characteristic for patients who convert to dementia than their initial scores. Conclusions: aMCI subjects treated with cerebrolysin with lower baseline cognitive functioning and subclinical depression have poor prognosis in terms of converting to dementia. Changes in the MMSE, Boston naming test, Digit span forward, and Wechsler scale subtest “Categorical associations” scores during the treatment course are more informative to identify patients who will develop dementia than their initial scores.
Cite this paper: Boksha, I. , Gavrilova, S. , Kolykhalov, I. , Fedorova, I. , Kalyn, I. , Selezneva, N. , Samorodov, A. , Miasoedov, S. and Mukaetova-Ladinska, E. (2014) Progression of Cognitive Deficit in Older People with Mild Cognitive Impairment Treated with Cerebrolysin. Health, 6, 2581-2591. doi: 10.4236/health.2014.619297.

[1]   Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Kokmen, E. and Tangelos, E.G. (1997) Aging, Memory, and Mild Cognitive Impairment. International Psychogeriatrics, 9, 65-69.

[2]   Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G. and Kokmen, E. (1999) Mild Cognitive Impairment: Clinical Characterization and Outcome. Archives of Neurology, 56, 303-308.

[3]   Petersen, R.C. (2004) Mild Cognitive Impairment as a Diagnostic Entity. Journal of Internal Medicine, 256, 183-194.

[4]   Golob, E.J., Johnson, J.K. and Starr, A. (2002) Auditory Event-Related Potentials during Target Detection Are Abnormal in Mild Cognitive Impairment. Clinical Neurophysiology, 113, 151-161.

[5]   Golob, E.J., Irimajiri, R. and Starr, A. (2007) Auditory Cortical Activity in Amnestic Mild Cognitive Impairment: Relationship to Subtype and Conversion to Dementia. Brain, 130, 740-752.

[6]   Schmidtke, K. and Hermeneit, S. (2008) High Rate of Conversion to Alzheimer’s Disease in a Cohort of Amnestic MCI Patients. International Psychogeriatrics, 20, 96-108.

[7]   Gavrilova, S.I., Fedorova, I.B., Roshchina, I.F. and Korovaitseva, G.I. (2007) Prognosis of the Syndrome of Mild Cognitive Impairment: The Data of the Biennial Follow-Up Study. Zh Nevrol Psikhiatr Im S S Korsakova, 107, 4-10.

[8]   Vemuri, P., Wiste, H.J., Weigand, S.D., Knopman, D.S., Trojanowski, J.Q., et al. (2010) Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD. Neurology, 75, 143-151.

[9]   Gavrilova, S.I., Kolykhalov, I.V., Fedorova, I.B., Selezneva, N.D., Kalyn, I.B., Roshchina, I.F., et al. (2010) Possibilities of Preventive Treatment of Alzheimer’s Disease: Results of the 3-Year Open Prospective Comparative Study on Efficacy and Safety of the Course Therapy with Cerebrolysin and Cavinton in Elderly Patients with the Syndrome of Mild Cognitive Impairment. Zh Nevrol Psikhiatr Im S S Korsakova, 110, 62-69.

[10]   Gavrilova, S.I., Fedorova, Y.B., Roshchina, I.F. and Korovaitseva, G.I. (2008) Prognosis of Mild Cognitive Impairment Syndrome: Data from a Two-Year Clinical Follow-Up Study. Neuroscience and Behavioral Physiology, 38, 129-134.

[11]   Korovaitseva, G.I., Shcherbatykh, T.V., Selezneva, N.V., Gavrilova, S.I., Golimbet, V.E., Voskresenskaia, N.I. and Rogaev, E.I. (2001) Genetic Association between the Apolipoprotein E (ApoE) Gene Alleles and Various Forms of Alzheimer’s Disease. Genetika, 37, 529-535. (Article in Russian)

[12]   Caselli, R.J., Dueck, A.C., Osborne, D., Sabbagh, M.N., Connor, D.J., Ahern, G.L., et al. (2009) Longitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect. New England Journal of Medicine, 361, 255-263.

[13]   Petersen, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., et al. (2001) Current Concepts in Mild Cognitive Impairment. JAMA Neurology, 58, 1985-1992.

[14]   Reisberg, B., Ferris, S.H., de Leon, M.J. and Crook, T. (1988) Global Deterioration Scale (GDS). Psychopharmacology Bulletin, 24, 661-663.

[15]   Morris, J.C. (1993) The Clinical Dementia Rating (CDR): Current Version and Scoring Rules. Neurology, 43, 2412.

[16]   Hamilton, M. (1960) A Rating Scale for Depression. Journal of Neurology, Neurosurgery & Psychiatry, 23, 56-62.

[17]   Hachinski, V.C. (1978) Cerebral Blood Flow Differentiation of Alzheimer’s Disease from Multi-Infarct Dementia. In: Katzman, R., Terry, R.D. and Bick, K.L., Eds., Alzheimer’s Disease: Senile Dementia and Related Disorder, Raven Press, New York, 97-104.

[18]   Folstein, M.F., Folstein, S.E. and McHugh, P.R. (1975) ‘Mini-Mental State’. A Practical Method for Grading the Cognitive State of Patients for the Clinician. Journal of Psychiatric Research, 12, 189-198.

[19]   Mattis, S. (1976) Mental Status Examination for Organic Mental Syndrome in the Elderly Patient. In: Bellack, L. and Karusu, T.B., Eds., Geriatric Psychiatry, Grune & Stratton, New York, 77-121.

[20]   Wechsler, D. (1981) Wechsler Adult Intelligence Scale-Revised. Psychological Corporation, New York.

[21]   Collie, A., Myers, C., Schnirman, G., Wood, S. and Maruff, P. (2002) Selectively Impaired Associative Learning in Older People with Cognitive Decline. Journal of Cognitive Neuroscience, 14, 484-492.

[22]   Takayama, Y. (2010) A Delayed Recall Battery as a Sensitive Screening for Mild Cognitive Impairment: Follow-Up Study of Memory Clinic Patients after 10 Years. Journal of Medical and Dental Sciences, 57, 177-184.

[23]   Dubois, B., Slachevsky, A., Litvan, I. and Pillon, B. (2000) The FAB: A Frontal Assessment Battery at Bedside. Neurology, 55, 1621-1626.

[24]   Brodaty, H., Gresham, M. and Luscombe, G. (1997) The Prince Henry Hospital Dementia Caregivers’ Training Programme. International Journal of Geriatric Psychiatry, 12, 183-192.<183::AID-GPS584>3.0.CO;2-J

[25]   Shulman, K.I., Shedletsky, R. and Silver, I.L. (1986) The Challenge of Time: Clock-Drawing and Cognitive Function in the Elderly. International Journal of Geriatric Psychiatry, 1, 135-140.

[26]   Sunderland, T., Hill, J.L., Mellow, A.M., Lawlor, B.A., Gundersheimer, J., Newhouse, P.A. and Grafman, J.H. (1989) Clock Drawing in Alzheimer’s Disease: A Novel Measure of Dementia Severity. Journal of the American Geriatrics Society, 37, 725-729.

[27]   Kaplan, E.F., Goodglass, H. and Weintraub, S. (1983) The Boston Naming Test. 2nd Edition, Lea & Febiger, Philadelphia.

[28]   Sudakov, S.A. (2010) Cluster Analysis in Psychiatry and Clinical Psychology: A Guide. [In Russian] Medical Information Agency, Moscow.

[29]   Morris, J.C., Storandt, M., Miller, J.P., McKeel, D.W., Price, J.L., Rubin, E.H. and Berg, L. (2001) Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease. JAMA Neurology, 58, 397-405.

[30]   Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.O., et al. (2004) Mild Cognitive Impairment-Beyond Controversies, towards a Consensus: Report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine, 256, 240-246.

[31]   De Jager, C.A., Milwain, E. and Budge, M. (2002) Early Detection of Isolated Memory Deficits in the Elderly: The Need for More Sensitive Neuropsychological Tests. Psychological Medicine, 32, 483-491.

[32]   De Jager, C.A., Schrijnemaekers, A.C., Honey, T.E. and Budge, M.M. (2009) Detection of MCI in the Clinic: Evaluation of the Sensitivity and Specificity of a Computerized Test Battery, the Hopkins Verbal Learning Test and the MMSE. Age and Ageing, 38, 455-460.

[33]   Elias, M.F., Beiser, A., Wolf, P.A., Au, R., White, R.F. and D’Agostino, R.B. (2000) The Preclinical Phase of Alzheimer Disease: A 22-Year Prospective Study of the Framingham Cohort. JAMA Neurology, 57, 808-813.

[34]   Schrijnemaekers, A.M., de Jager, C.A., Hogervorst, E. and Budge, M.M. (2006) Cases with Mild Cognitive Impairment and Alzheimer’s Disease Fail to Benefit from Repeated Exposure to Episodic Memory Tests as Compared with Controls. Journal of Clinical and Experimental Neuropsychology, 28, 438-455.

[35]   De Jager, C.A. (2004) Changes over Time in Memory, Processing Speed and Clock Drawing Tests Help to Discriminate between Vascular Cognitive Impairment, Mild Cognitive Impairment and Alzheimer’s Disease. Neurological Research, 26, 481-487.

[36]   Roses, A.D., Saunders, A.M., Corder, E.H., Pericak-Vance, M.A., Han, S.H., Einstein, G., et al. (1995) Influence of the Susceptibility Genes Apolipoprotein E-Epsilon 4 and Apolipoprotein E-Epsilon 2 on the Rate of Disease Expressivity of Late-Onset Alzheimer’s Disease. Arzneimittel-Forschung, 45, 413-417.

[37]   Narasimhalu, K., Ang, S., De Silva, D.A., Wong, M.C., Chang, H.M., Chia, K.S., et al. (2009) Severity of CIND and MCI Predict Incidence of Dementia in an Ischemic Stroke Cohort. Neurology, 73, 1866-1872.

[38]   Alvarez, X.A., Lombardi, V.R., Corzo, L., Pérez, P., Pichel, V., Laredo, M., et al. (2000) Oral Cerebrolysin Enhances Brain Alpha Activity and Improves Cognitive Performance in Elderly Control Subjects. Journal of Neural Transmission. Supplementum, 59, 315-328.

[39]   Alvarez, X.A., Cacabelos, R., Laredo, M., Couceiro, V., Sampedro, C., Varela, M., et al. (2006) A 24-Week, Double-Blind, Placebo-Controlled Study of Three Dosages of Cerebrolysin in Patients with Mild to Moderate Alzheimer’s Disease. European Journal of Neurology, 13, 43-54.

[40]   Chen, N., Yang, M., Guo, J., Zhou, M., Zhu, C. and He, L. (2013) Cerebrolysin for Vascular Dementia. Cochrane Database of Systematic Reviews, 1, CD008900.

[41]   Damulin, I.V., Koberskaia, N.N. and Mkhitarian, E.A. (2007) The Effect of Cerebrolysin on Moderate Cognitive Impairment in Cerebral Vascular Insufficiency (a Clinical and Electrophysiological Study). Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 107, 32-38. (Article in Russian)